ArticleOncoTargets and therapy2019

Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy.

Rudolph M Navari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.